Neoprobe, Cardinal Health ink terms for Lymphoseek distribution:
This article was originally published in Clinica
Executive Summary
Manufacturer of oncology and cardiovascular products Neoprobe has signed a non-binding term sheet with Cardinal Health for the exclusive US marketing and distribution rights to its Lymphoseek radioactive lymphatic mapping targeting agent. Cardinal Health, headquartered in Dublin, Ohio, will provide Neoprobe with a distribution network of more than 150 nuclear pharmacies, and its wholesale distribution operations to in-hospital nuclear pharmacies. Neoprobe, also located in Dublin, Ohio, is developing Lymphoseek for use with hand-held gamma detection devices, and is preparing to submit a phase III multicenter clinical trial to the FDA.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.